



Implementation of the RAS Program

David C. Heimbrook, Ph.D.
CEO, SAIC-Frederick

Presentation to Joint BSA / NCAB Meeting


June 24, 2013

Frederick National Laboratory Missions

What is RAS, and why is it so important?


RAS stands for **R**at **S**arcoma viral oncogene homolog, and is a protein which is a key regulator of signal transduction in normal and cancerous cells

- Four flavors : **H**arvey, **K**irsten (A & B), and **N**euroblastoma




HRAS

(Wikimedia commons)



Mutated RAS is found in ~33% of human cancers, is currently undruggable, and enables resistance to many existing cancer therapies

Etiology of the RAS Program at FNLCR



Full-Spectrum Research & Development at FNLCR

Frederick
National
Laboratory
for Cancer Research

Research & Development

- **Basic Research:** New knowledge about AIDS and cancer
- **Applied R&D:** New diagnostics and therapeutics
- **Clinical Research:** Clinical trials and laboratory analysis
- **cGMP manufacturing:** Biologicals and vaccine production



Specialties

- Genomics, proteomics, and metabolomics
- Bioinformatics and imaging
- Nanotechnology
- Animal models
- Tumor cell biology and virology
- Immunology and inflammation



Customers


- NCI, NIH, and external academic and commercial biomedical scientists

All FNLCR assets and expertise are available to the RAS program


Implementing “National Missions” at FNLCR *The RAS Hub*

Frederick
National
Laboratory
for Cancer Research


Essential capabilities....



Genetics and Genomics




Proteins and Proteomics



Imaging and Nanotechnology



Advanced Biomedical Computing



Cell Biology

...integrated into a brand new
state-of-the-art Research Facility



Advanced Technology Research Facility
Opened June 2012



Integrated *in vivo* support at
Frederick & Bethesda

Operationalizing the RAS Program

Hub and Spoke model

Intramural Labs



Extramural NCI-Supported Labs



FNLCR – The Hub



Biotechs



Pharma



Contract Research

Hub Partnerships Facilitated through NCI and **Contractor** Mechanisms

Material Transfer Agreement (MTA)

- Research materials transferred (in or out); research plan
- No fees; No joint IP

Technical Services Agreement

- Purchase of contractor-developed assays or reagents
- Minimal paperwork; Assay list online
- Cost recovery only

Collaboration Agreement

- Research materials transferred (in or out);
- Research plan developed
- Both contribute intellectually; no \$\$ to NCI

Cooperative Research & Development Agreement (CRADA)

- R&D collaboration both partners contribute intellectually
- Both contribute resources; can include \$\$ to NCI
- Both NCI and **Contractor** mechanisms

The RAS Program

Funding Model

- **Funding for FNLCR RAS Hub**

- Approximately \$10 M / yr from NCI-directed re-prioritization of ongoing activities within the existing FFRDC contract - No new money
 - The Advanced Technology Program “Pivot” re-orientes a predominantly intramural effort towards driving the RAS Hub
 - Additional “one-time” funds from within the existing contract facilitate start-up activities
- This funding supports ongoing research activities within the Hub, as well as initial phase of subcontracts between the Hub and external laboratories

- **Funding for RAS Spokes**

- Contract Research Organization – subcontracts from FNLCR RAS Hub
- Pharma, Biotech – Self-funded
- Academic : Some subcontracts from FNLCR RAS Hub;
 - Existing and future grantees working on RAS will have the opportunity to participate in RAS program

The RAS Program

Oversight and Governance

- **Oversight**

- An NCI-Frederick Advisory Committee (NFAC) subgroup will be formed
 - Will include NFAC members and representatives from academia and industry (TBD)

- **Research Program Prioritization**

- Joint recommendations by RAS Program leadership (Frank McCormick and SAIC-F leadership) and RAS Program oversight group, with concurrence by NCI Leadership (Drs. Varmus and Lowy)